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*Valvular AF is also an important public health problem in LMIC. Although AF is the main focus of this Roadmap, much of the 
recommendations on treatment and health system roadblocks can be applied to atrial flutter as well. 
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1 Background and Aim 
It is now well known that the number of deaths from non-communicable diseases (NCDs) is increasing globally, 
particularly in low-and middle-income countries (LMICs). (4, 5) Many NCDs, including cardiovascular diseases 
(CVD) and related conditions, can be detected early and treated with cost-effective interventions, thus preventing 
costly hospitalizations and death. However, this requires coordinated health system responses built around 
evidence-based strategies. In many LMICs, health resources are scarce, and identifying priority, cost-effective 
interventions for CVD and related conditions is vital for planning effective health system responses to these 
diseases.  
The aim of the World Heart Federation (WHF) Roadmap Initiative is to provide guidance on priority interventions 
on a global level that can be adapted to regional and national contexts. The Initiative does so by focusing on a few 
priority interventions for CVD and related conditions that are i) supported by high-quality evidence of a measurable 
reduction in CVD, ii) feasible in various country contexts and iii) affordable and cost-effective. The WHF 
Roadmaps not only identify key interventions, but also aim to document barriers to implementing these 
interventions and to identify potential strategies for overcoming them. Roadmaps for addressing gaps in secondary 
prevention of CVD, tobacco control and hypertension have already been published and are in the implementation 
phase. The focus of this WHF Roadmap is non-valvular atrial fibrillation (AF) *, in particular the detection and 
management of AF in LMICs using evidence-based drug therapy to prevent stroke.  
 
2 Atrial fibrillation: Epidemiology and burden of disease 
AF is the commonest clinically significant arrhythmia. (8) A Roadmap that promotes national policies and health 
systems approaches to the management of AF and provides tools and solutions for adaptation at a regional and 
national level is particularly timely. Between 1990 and 2013, although the global prevalence rate of AF decreased 
slightly, the overall number of AF cases increased, according to the Global Burden of Disease Study (GBD) 2013 
(Table 1). (9) The morbidity burden associated with AF, as measured by disability-adjusted life years (DALYs), 
also increased. Estimates of prevalence of AF, and DALYs associated with AF, are likely to underestimate true 
burden due to the high prevalence of asymptomatic AF.(8) AF is also associated with high costs incurred by 
individuals, health care systems and economies. (8, 10-13) Common clinical outcomes associated with AF are 
outlined in Box 1. (14) Among other clinical outcomes, AF is associated with increased risk of stroke and is found 
in one third of all ischemic strokes. (15) 
 
Table 1. Global burden of AF in 1990 and 2013, data from Global Burden of Disease Study 2013(9)  
 
Global Prevalence Cases* (All ages) Rate per 100,000 (Age-standardized) 
Year Mean 95% UI** Mean 95% UI** 
1990  6841147     (6602764, 7114686) 213.7 (205.9, 222.6) 
2013 11178627 (10655102, 11683727) 191.3 (182.1, 200.1) 
     
Global DALYs Cases* (All ages) Rate per 100,000 (Age-standardized) 
Year Mean 95% UI Mean 95% UI** 
1990   854714   (693332, 1049075) 26.7 (21.7, 32.7) 
2013 1888690 (1590032, 2224863) 32.5 (27.5, 38.2) 
* Cases rounded to the nearest whole number 
**UI = uncertainty interval 
Box 1. Common clinical outcomes as a consequence of AF (14) 
 
 
 
 
 
Past GBD studies have also suggested that the burden of AF varies among regions, with high-income countries 
experiencing higher prevalence, incidence, DALYs and mortality associated with AF than LMICs.(8) However, 
estimates of the extent of this difference should be interpreted with caution, as the lower rates of AF documented 
in developing countries may be related to weaker surveillance systems and geographical disparity in published data. 
(8) Moreover, in countries at all levels of development, a substantial proportion of AF cases is asymptomatic, (16) 
making them more difficult to detect without advanced medical technology. Research from the RE-LY registry also 
suggests that patients with AF in LMICs tend to be younger, are more likely to experience heart failure, and are less 
likely to be managed according to published AF guidelines (i.e. patients with AF in LMICs show lower use of 
OACs and lower time in therapeutic range). (1) 
 Increased mortality  
 Increased risk and severity of stroke  
 Increased risk of hospitalization  
 Reduction in quality of life  
 Reduction of exercise capacity  
 Increased risk of heart failure  
Estimated differences in AF burden between developed and developing countries should also be interpreted in light 
of the risk factor profile of this condition. While European ancestry has been identified as one risk factor for AF 
(compared to African and Asian ancestry) (17, 18), the risk of AF mainly increases with age (19) and is higher 
among those with a range of CVD such as myocardial infarction and CVD risk factors such as hypertension, diabetes 
mellitus, obesity, smoking, and alcohol use. (17, 20-26) As these risk factors continue to increase in developing 
countries, so likely will the burden of morbidity and mortality from AF. This burden may be further compounded 
by the shortage of health care resources in many developing countries, as successful management of AF requires 
consistent and long-term interaction between the patient and health care system. 
3 Key interventions for detection, diagnosis and management of AF  
3.1 Primary prevention 
As with all health conditions, primary prevention of AF, i.e. reducing the risk of first onset by targeting modifiable 
risk factors (Figure 1), is the ultimate goal of the medical and public health community, but is made challenging by 
persistent gaps in knowledge regarding determinants of AF. Models such as CHARGE-AF (27) have been 
developed to predict risk of AF, and to identify patients who may benefit from preventative interventions, based on 
age, race, height, weight, blood pressure, smoking, use of antihypertensive medication, diabetes, and history of 
myocardial infarction and heart failure.  However, this model has only been validated for populations in the United 
States and Western Europe. (27) Moreover, although the benefits of interventions to manage risk factors such as 
weight, blood pressure, smoking and diabetes for health outcomes generally are well-established and relevant to 
populations globally, primary prevention trials for AF have yet to establish a role for interventions for specific risk 
factors. There is an urgent need for research that can inform primary prevention efforts for AF in more 
geographically and racially diverse populations, while also evaluating the effectiveness of preventative strategies 
aimed at reducing the risk of AF globally.(28)  
 
Figure 1: Stages of AF and intervention strategies 
 
 
 
 
 
Normal rhythm Symptomatic AF Asymptomatic AF Complications 
Primary prevention Screening/diagnosis Diagnosis/ Management 
3.2 Screening  
While a shortage of evidence of AF determinants and prevention strategies restricts primary prevention efforts, 
there is stronger evidence that early detection and treatment can reduce morbidity and mortality due to AF. 
Guidelines recommend that all patients who present with symptoms of AF - breathlessness, palpitations, 
syncope, chest discomfort or stroke - should have their pulse checked for irregularities as well as 12-lead 
ECG.(29) Prolonged ECG monitoring may be especially useful in patients with heart failure and post-stroke, in 
order to enhance detection and reduce health resource utilization and costs, depending on local resource and 
expertise. This strategy should be complemented by screening for asymptomatic AF. In a large randomized trial 
comparing routine practice versus targeted population-based screening and opportunistic screening, opportunistic 
palpation (pulse-taking) of patients aged 65 and over, with or without known AF risk factors (with follow-up 
electrocardiogram (ECG) for those with an irregular pulse), was found to be the cheapest and most effective method 
of screening for AF (opportunistic screening was found to detect similar numbers of new cases compared with 
systematic screening (1.64% v 1.62%, and requires fewer resources). (30) One limitation of opportunistic pulse 
palpation is the high number of false positives that can result in unnecessary ECGs. (While unnecessary ECGs are 
not harmful per se, accurate interpretation of ECGs can only be done by specifically-trained staff, of which there 
may be few in low-resource settings.) A recent meta-analysis has suggested that newer technologies such as 
modified blood pressure monitors (BPMs) and single-lead ECGs may be more accurate in detecting AF,(31) and 
at-home BPMs have been estimated to reduce strokes and save costs by the UK National Institute of Clinical 
Evaluation. (32) However, these technologies are not widely available and therefore their use for large-scale 
screening initiatives is not yet feasible. 
3.3 Diagnosis 
Although an irregular pulse may point to AF, an ECG is still required to confirm the diagnosis. A negative ECG 
does not exclude the diagnosis of AF by pulse-taking since AF may be paroxysmal (transient). In patients with 
suspected AF, diagnosis should be confirmed using a single-lead rhythm strip or 12-lead ECG documenting 
>30 seconds of AF. (33, 34) A 12-lead ECG can detect other abnormalities such as left ventricular hypertrophy, 
ischemia, and other clinical features. At first diagnosis, AF can be classified as one of four types: paroxysmal (self-
terminating, usually within 48 hours), persistent (lasts longer than 7 days), long-standing persistent (has lasted one 
year or more) or permanent (when presence of arrhythmia is accepted and no rhythm control, i.e. stabilizing sinus 
rhythm, is attempted). Although paroxysmal AF is associated with somewhat lesser risk of thromboembolism than 
non-paroxysmal AF, (35) all types of AF are associated with sufficiently increased risk of thromboembolism, 
especially stroke, (36) making detection of even paroxysmal AF critical. (For any pattern of AF, a prime determinant 
of risk of thromboembolism and prognosis is the presence of CVD comorbidities such as hypertension or diabetes 
(see next paragraph)). If AF is not detected with single-lead rhythm strip or 12-lead ECG, a 24-hour ambulatory 
monitor (Holter) or other long-term ECG monitoring may be necessary. Only a few studies exist comparing 
methods and duration of ECG monitoring but prolonged monitoring has been recommended for highly symptomatic 
patients, and those with cryptogenic stroke. (14, 37-40) Inexpensive smartphone-based rhythm monitoring 
equipment has potential applications in LMICs, but systems for deployment and validation require further 
development and investigation.  
Presence of CVD and other risk factors affects the risk of stroke and prognosis in patients with AF. Patients with 
confirmed AF should undergo a thorough clinical assessment including an analysis of family history, risk 
factors and concomitant disease, in order to assess stroke risk. The risk factors for stroke among AF patients 
for which there is an evidence base include prior stroke/transient ischemic attack (TIA)/thromboembolism, age, 
hypertension, diabetes and structural heart disease. (14, 41, 42) One tool for evaluating stroke risk among AF 
patients is the CHA2DS2-VASc score. (43) The CHA2DS2-VASc is a point-based risk stratification system that 
assigns 2 points to a history of stroke/TIA/thromboembolism and age > 75, and 1 point each to a history of 
congestive heart failure, hypertension, diabetes or vascular disease, age 65-74 or female sex. Oral anticoagulant 
therapy is recommended for those with a CHA2DS2-VASc of 2 or above.(33) In East Asian people, there is evidence 
that the risk benefit balance of anticoagulation may justify use of a lower cut-off (e.g., CHA2DS2-VASc score of 1, 
younger age). (44)  In addition to a thorough clinical examination, all patients with AF should also undergo an 
echocardiogram to assess for underlying heart disease that requires treatment. (14, 29) Heart failure was more 
common among individuals with AF in Africa than in other regions of the world. (1) The absence of symptoms 
among patients presenting with AF does not suggest lower risk of stroke and these asymptomatic patients should 
also undergo thorough clinical assessment. (16, 45, 46)  
3.4 Management 
After clinical assessment of confirmed AF cases and based on stroke risk, anticoagulant therapy should be 
initiated, to reduce risk of stroke and systemic thromboembolism, while also taking into account the risk of 
major bleeding (discussed below). Anticoagulation for medium-and high-risk non-valvular AF is identified as a 
recommended policy option by the World Health Organization (WHO) in the WHO Global Action Plan for the 
Prevention and Control of NCDs 2013-2020. (47) Until recently, warfarin and other vitamin K antagonists were the 
only class of oral anticoagulants (OACs) available, but since 2009, non-vitamin K anticoagulants (NOACs) have 
been introduced that reduce the need for frequent monitoring and the side effects associated with vitamin K 
antagonists, are as effective as warfarin in reducing stroke and may be associated with a lower risk of bleeding. (48) 
Evidence suggests that NOACs may be cost-effective options for stroke prevention in AF patients, (49) although 
possibly more so in settings with poor warfarin management. (50) Nevertheless, warfarin remains the most widely 
available anticoagulant and is the only anticoagulant on the World Health Organization’s Essential Medicines list. 
(51)  Aspirin, which is widely used as an antithrombotic therapy for AF is neither effective nor safe and has been 
written out of most published guidelines. (52) The combination of aspirin plus clopidogrel is more effective than 
aspirin alone but less effective than warfarin when the time in therapeutic range is reasonably well managed, and 
has no advantage over warfarin in terms of major bleeding. (53, 54) 
The decision to initiate anticoagulant therapy to reduce risk of stroke must be weighed against the risk of major 
bleeding complications associated with anticoagulant therapy, the most dangerous of which is intracerebral 
hemorrhage (ICH). (33, 55) Prior to initiating anticoagulant use, risk of bleeding should be assessed. Assessment 
tools for identifying risk factors for bleeding have been recommended by some national guidelines in high-income 
countries, including risk factors such as hypertension, abnormal renal function, abnormal liver function, prior stroke, 
prior major bleeding or predisposition to bleeding, labile international normalized ratio (INR), age > 65, prior 
alcohol or drug usage and medication usage predisposing to bleeding (e.g. antiplatelet agents, non-steroidal anti-
inflammatory drugs), (56) (33, 57) but these tools have not been validated in LMICs. Some research suggests that 
those of Chinese ethnicity are more susceptible to ICH than those of European descent. (58)  If bleeding risk factors 
are present with increased bleeding risk, in general, anticoagulant therapy should not be withheld, but regular review 
and attempts to address bleeding risk factors are recommended. (33) Control of hypertension and avoidance of 
concomitant antiplatelet therapy are among the more important strategies to reduce the risk of major bleeding in 
anticoagulated patients with AF. 
While anticoagulant therapy is the only proven way to reduce stroke or systemic embolism among patients with 
AF, arrhythmia management therapies may reduce AF symptoms and improve patient quality of life. (59) The first 
aim of arrhythmia management is to slow the ventricular rate to a resting rate of <100 beats per minute.  Initiation 
of drug therapy to stabilize sinus rhythm (rhythm control) is based on extent of symptoms and patient and physician 
values and preferences as currently there is no evidence that rhythm control therapies reduce the risk of stroke. (59) 
After diagnosis and a treatment plan are established, most patients with AF can be followed in primary health care 
(PHC) to monitor heart rate and rhythm and to reassess risk stratification. (29) Monitoring of AF patients in PHC 
also provides the opportunity to monitor and treat co-morbid cardiovascular conditions, (60, 61) in particular 
hypertension, heart failure, diabetes and valvular abnormalities. Conversely, in PHC, individuals presenting with 
these conditions have a high prevalence of AF, which should be borne in mind during their assessment. Although 
valvular AF is not the focus of this Roadmap, management of AF should include consideration of the management 
of rheumatic heart disease (RHD) and valvular heart disease, as these diseases are common in LMICs and a large 
proportion of those suffering from them (30-40%) develop AF. (62) Further guidance on management of, and health 
system responses to RHD is included in the WHF RHD Roadmap. 
3.5 The “ideal” patient care pathway for AF patients 
Based on the evidence cited above, Figure 2 outlines key recommendations for detection, diagnosis and 
management of AF, or the “ideal patient pathway" for AF patients. This includes i) screening of individuals with 
known AF risk factors and opportunistic screening of patients 65 years or older coming in for review, ii) 12-lead 
ECG to confirm suspected persistent or permanent AF, iii) assessment of stroke risk and iv) initiation of 
anticoagulant therapy, combined with lifestyle modification advice if appropriate (e.g. weight reduction, smoking 
cessation). While rate and rhythm control are important steps for management of symptoms, they are included in a 
different colour as this pathway is intended to outline only the bare minimum evidence-based interventions for 
reducing mortality associated with AF. However, it should be noted that several other opportunities to change 
prognosis in AF exist, e.g. prevention and management of tachycardiomyopathy. 
 
 
Figure 2: The ideal patient care pathway for AF patients 
 
   
4 Knowledge-Practice Gaps  
Despite evidence supporting opportunistic pulse palpation of patients 65 years of age and older, with confirmatory 
diagnosis using 12-lead ECG, (30) the pulse is not routinely palpated in over 65 year olds.  It should be noted that 
the basis of this pragmatic recommendation is a single randomised controlled trial in a high-income country where 
cardiology review was widely available, and therefore more context-specific research from LMICs is needed. Also 
despite guideline-recommended prevention of stroke with anticoagulant therapy,(33) large gaps in implementation 
of this therapy remain. (15) These knowledge-practice gaps are present worldwide. The GARFIELD registry, a 
study of 19 countries in 2009-2011, revealed that 38.0% of patients with high risk of stroke had not received 
anticoagulant therapy, whereas 42.5% of those at low risk (score 0) did. (2) The PINNACLE Study in the United 
States found that less than half of high-risk patients were receiving OAC therapy. (63) In the EURObservational 
Research Programme-Atrial Fibrillation (EORP-AF) general registry of nine European countries, while use of 
OACs was higher (approximately 81-81% of high stroke risk patients), persistence of therapy was still not optimal 
(84% of those prescribed with vitamin K antagonist remained on therapy 1 year later), and despite guidelines, 
antiplatelet therapy (commonly aspirin) was used in 15% of low risk patients, and in 31% of high-risk patients. (3)  
Although present worldwide,(3, 64) these gaps vary in degree across countries, appearing to be most prominent in 
LMICs. Data from LMICs are scarce but what does exist, points to very low rates of oral anticoagulation therapy 
among AF patients. (1, 28, 65) A review of existing literature (65) found that estimated rates of anticoagulant use 
range from only 2.7% to 50% in China, (65-67) 26% to 44% in Pakistan, (68)16% in Malaysia,(69) from 46.7% to 
57.8% in Brazil, (70) 36.8% in Mexico, (71) 72.7% in Argentina, (72) 33% in South Africa, (73) 34.2% in 
Cameroon, (74) from 11.5% (rural) to 26.5% (urban) in Zimbabwe, (75) 62% in Senegal, (76) from 30.1% to 67.3% 
in Turkey, (77, 78) 13%-53.9% in Serbia, (79) 27% in Kosovo (80) and 7.1% in Moldova. (81) The Gulf SAFE 
registry revealed similarly low rates of anticoagulation use (49% of patients) in six Gulf countries (Bahrain, Kuwait, 
Oman, Qatar, United Arab Emirates and Yemen). (6) 
Most evidence on AF knowledge-practice gaps in LMICs focuses on gaps in management of stroke risk among AF 
patients with OACs. However, there is evidence of gaps across the continuum of care for AF globally, which are 
likely to apply in LMICs. For example, research in Canada suggested that non-cardiologist physicians lack sufficient 
knowledge, skills and confidence to diagnose AF, with diagnosis of paroxysmal or asymptomatic AF being 
particularly challenging, and that continuous professional education and development is necessary to strengthen the 
capacity of physicians to navigate AF screening and diagnosis guidelines. (82)    
5 Roadblocks and Solutions 
Table 2 identifies potential 'roadblocks' along the ideal patient pathway for AF screening, diagnosis and 
management. Potential roadblocks and solutions were identified through a review of published literature as well as 
through consultation with an expert committee, comprised of experts in AF clinical management and health systems 
research in LMICs. These roadblocks are presented in terms of barriers to geographical accessibility, availability, 
affordability and acceptability of AF health care, drawing on existing frameworks for identifying health systems 
barriers in LMICs. (83-85) Also outlined are strategies for addressing these roadblocks and specific potential 
solutions for executing these strategies. 
 
 
 
  
Table 2: Roadblocks, strategies and potential solutions for achieving effective AF management 
Dimension Roadblock Strategy Potential solutions 
Geographic 
accessibility 
Long distances to clinics result 
in low numbers of rural patients 
presenting to clinics for 
screening. 
1. Improve accessibility of screening for 
rural populations. 
 
 
 
2. Strengthen capacity for ECG testing 
in remote areas. 
1. Train community health workers or pharmacists to 
screen for possible AF with pulse-checking in non-
clinic settings 
Educate at risk-populations (e.g. those 65+ years of 
age) to self-screen with pulse checks. 
2. Implement novel telemedicine technologies (e.g. 
transmission of ECG results from rural areas to urban 
facilities).  
Availability Shortage of health care 
professionals with training in 
AF, including interpretation of 
ECG, initiation of  and 
monitoring of anticoagulation 
therapy. 
1. Raise awareness of AF among health 
care professionals.  
 
 
 
 
 
 
2. Reduce dependence on highly trained 
medical staff for AF screening and 
management. 
1. Conduct awareness campaigns through health care 
professional networks;  
 
Improve post-graduate training and continuous 
medical education (CME) 
 
Develop simple and locally applicable AF guidelines.  
 
2. Implement non-physician health worker (NPHW)-
managed anticoagulation program  
Affordability OACs potentially unaffordable 
for patient households, resulting 
in non-adherence to treatment 
regime. 
1. Improve affordability of OACs 1. Provide universal health care coverage for essential 
medicines 
 
2.   Implement internationally recognized policies for the 
reduction of essential medicine costs (Box 2). 
Acceptability Reluctance of physicians and 
patients to initiate 
anticoagulation therapy   
 
Lack of awareness of 
importance of persistent 
adherence to oral anticoagulant 
therapy. 
1. Improve awareness of and capacity 
for managing OAC therapy among 
physicians.  
 
2. Improve patient understanding of 
importance of OAC therapy and 
capacity to adhere to therapy. 
1. Conduct country-specific training on OAC therapy 
management and support programmes for non-
cardiologist health care professionals. 
 
2. Develop and implement country-specific patient 
education, medical literacy and support programmes 
for diagnosed AF patients on OAC therapy. 
 
3. Conduct research into feasibility of self-
monitoring programmes for patients on OAC 
therapy in LMIC. 
 
 
  
5.1 Improving accessibility and availability of screening for rural populations 
This Roadmap recommends that screening for AF is best conducted via opportunistic palpation (pulse-taking) of 
patients aged 65 and over, with or without known AF risk factors, with follow up ECG for those with an irregular 
pulse. Following this recommendation may be challenging, however, in remote settings in LMICs. In these settings, 
when at-risk individuals present at clinics, health professionals who are trained in interpretation of ECGs may not 
always be available. This may make the diagnosis of paroxysmal AF particularly difficult as it would require 
multiple ECG measurements to detect. Novel technologies that allow for cardiac rhythm assessment by non-
specialist health care workers may reduce the dependence on specialists for AF screening. (86) These include 
approaches for measuring pulse irregularity with inexpensive tools such as oscillometric blood pressure devices, 
(87) smart phones, (88, 89) or hand-held ECG devices that facilitate multiple ECG measurements. (88, 89) As 
mentioned above, however, these technologies are not yet readily available in LMICs; they have not been tested in 
these settings and the training and support required to implement them effectively must be considered. (86) New 
research on the feasibility of a non-physician health worker (NPHW)-led screening AF program in community 
health centres in China is planned and will offer valuable evidence of the effectiveness of such programs. In the 
meantime, experiences in successful training of NPHWs to screen for CVD (90, 91) and cancer (92) in LMICs may 
provide useful insights for implementation of non-specialist screening programs for AF.  
The field of telemedicine may also provide opportunities for addressing trained health care professional shortages  
in LMICs, (93, 94) with some findings suggesting that transmission of ECG results from remote, rural areas to 
urban facilities may improve detection of cardiovascular disease generally.(95) However, the effectiveness and 
cost-effectiveness of telemedicine in LMICs generally, (94-96) and specifically for detection of AF, has not been 
sufficiently evaluated and requires further research. Any strategies that make use of novel technologies for detection 
of AF will only be effective in reducing mortality associated with AF if OAC treatment is also available and 
affordable to those with diagnosed AF, and if structures are in place for the successful management of OAC therapy. 
5.2 Improving the affordability of OACs 
Any effort to reduce mortality associated with AF will only succeed if drug treatment, whether warfarin or NOACs, 
is readily available to those who need it, without causing undue financial hardship. (47) The affordability of warfarin 
specifically has not been studied, but evidence of a link between poor adherence to OACs and poverty, (97, 98) of 
the unaffordability of other CVD medications in LMIC (99) and the of catastrophic impact of health care costs for 
CVD generally (100, 101) may provide some indication of the likely burden that most chronic CVD medication 
costs impose on patient households. Currently, the affordability of NOACs in LMICs in uncertain, (102) and 
research on the cost-effectiveness of these drugs in these settings is needed. The WHF Roadmap for secondary 
prevention of CVD (61) identified strategies that have been previously recommended to increase the  affordability 
of CVD medications (103) and NCD medications generally. (104)These strategies are relevant to OAC drug 
therapies (Box 2). 
Box 2. Strategies for improving the affordability of CVD medications (103) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3 Reducing dependence on highly trained medical staff for AF management 
Dependence on medical specialists for AF treatment management can be challenging in LMIC settings that suffer 
from a shortage of highly-trained medical professionals. Research from the United Kingdom and the Netherlands 
has suggested that nurse-led management of AF treatment, with the use of computerized decision support systems 
and near-patient testing in a primary-care setting, can be an effective (105) and cost-effective (106) alternative to 
hospital-based management. Novel interventions for improving management of AF by family physicians in LMICs, 
supported by NPHWs are currently being studied (Box 3) and the results will provide valuable insights for how to 
increase the role of family physicians and NPHWs across the AF patient treatment pathway.  
Box 3: The IMPACT-AF trial in India 
 
 
 
 
 
1. Provide free essential drugs through universal health coverage. 
 
2. Increase the efficiency of the medication supply chain to promote access to 
medicines within existing health budgets (through more efficient selection, 
quantification and forecasting, procurement, storage, and distribution of 
medications). 
 
3. Promote the use of high-quality, safe and efficacious generic medications by 
overcoming legal barriers relating to patents and licenses in LMIC. 
 
4. Develop policies to reduce end-user prices, including regulating retail mark-
ups and eliminating tariffs on medicines. 
 
5. Engage the pharmaceutical industry to price CVD medicines at affordable 
levels in LMICs. 
 
The IMPACT-AF trial is testing the effectiveness of a comprehensive customized 
intervention for increasing the rate and persistence of use of OAC in patients with AF in five 
LMICs. In India the intervention will involve training NPHWs to educate patients in i) AF, stroke 
and recognizing the symptoms of a stroke, ii) the importance of oral anticoagulants to prevent 
stroke, and precautions to be taken while on warfarin therapy (as most Indian AF patients are on 
warfarin) and iii) the importance of medication adherence, identifying barriers in non-adherent 
patients and providing strategies to overcome those barriers. Diaries are given to patients to allow 
them to record days when they take medications, and included educational content. NPHWs are 
trained to follow-up patients, monitor INR, identify non-adherent patients and barriers to 
treatment adherence and support the patient toward getting back on treatment. The intervention 
also includes an educational intervention for physicians hosted at Duke University, consisting of 
webinars and access to guidelines on the use of OACs in AF. 
5.4 Improving capacity for management of OAC therapy among patients 
 
Successful management of stroke risk with OAC therapy among AF patients requires maintenance of INR within a 
target therapeutic range through regular monitoring and dose adjustments. Over or under-coagulation can result in 
thrombotic or hemorrhagic events. (107) The risks associated with OAC therapy are an important factor in physician 
and patient preferences regarding initiation of OAC, (108) and perhaps even more likely so in LMIC contexts where 
regular visits to a physician may be difficult due to travel distances, long wait times or high out-of-pocket costs. 
(47, 85, 109) Research from high income countries has suggested that self-management of OAC therapy among AF 
patients, with appropriate support and education, may be at least as effective as physician monitoring in reducing 
risk of thromboembolism, (110) and possibly more cost-effective. (111) Self-monitoring requires the patient 
measure the INR using a point-of-care device and self-adjust, if necessary, their dose of warfarin using a nomogram 
(dose prediction chart). (111, 112) However, evidence surrounding self-monitoring of OAC among AF patients, 
and the necessary elements for success of such interventions remains limited, and what exists has focused on high-
income countries alone. Further research is required on the potential for patient self-monitoring of OAC therapy as 
a means of reducing risk of thrombotic or haemorrhagic events in LMICs. Such research should be interpreted in 
light of different contextual factors, in particular that of the likely increase of the availability and affordability of 
NOAC's in LMICs, which reduce the need for improved INR monitoring.  
5.5 Strengthening Health Information Systems 
As noted above, there is a paucity of data on the incidence and quality of care of individuals with AF 
globally, and in particular in LMICs. Without this information, resource allocation for the solutions 
proposed here or other strategies to improve AF detection, diagnosis and treatment in any country is 
unlikely to be evidence-based and efficient. In order to support the planning and monitoring of AF 
interventions, health information systems must be developed. These should be simple, representative, 
context-appropriate and timely, and be established as part of a larger NCD surveillance strategy. Some 
existing AF registries are identified in Box 4. Further guidance on the development of health 
information systems for high and middle-income countries (e.g. national or regional registries and 
electronic health records) as well as low-income countries (e.g. periodic representative surveys), is 
provided in the WHF Roadmap on secondary prevention of CVD. (61) 
 
Box 4: Examples of international AF registries  
  
 
 
 
6 Adapting the AF Roadmap to regional and national contexts 
The AF and other WHF Roadmap provide general guidance on screening, diagnosis and management of AF, 
identify roadblocks to implementing evidence-based approaches in LMICs and suggest potential strategies to 
overcoming these. The application of these strategies to specific contexts must be considered further to adapt 
region- or country-specific Roadmaps. The WHF has described the process of producing region- and country-
specific Roadmaps. (113)  
National roadmaps should be developed within multi-sectoral partnerships, including inter-governmental 
organizations, heart health advocacy foundations, cardiovascular scientific organizations, healthcare leaders, 
providers from primary and specialized care, private-sector stakeholders and people affected by CVD (including 
patients and caregivers). To be successful, they will also require effective advocacy towards policy makers and 
politicians in national governments. 
The necessary steps for adapting the WHF AF Roadmap at the national level include (Figure 3): 
1. Develop and convene a multi-sectoral coalition to adapt the global Roadmap to local circumstances. 
2. Conduct a situation analysis of the health system for AF, including epidemiologic profiling, relevant 
policies and assets. 
3. Conduct policy dialogues with multiple local stakeholders. Local problems, specific barriers and potential 
solutions should be discussed and appropriate strategies selected according to context. 
4. Develop a plan to evaluate the implementation of the selected strategies. 
Figure 3: Adapting the WHF Roadmaps at the national level. (113) 
RE-LY registry (1)- 47 countries across all world regions 
Garfield-AF registry (2) – 19 countries worldwide with 34 total planned. 
EORP-AF European registry (3) – 9 European Society of Cardiology member countries 
Gulf SAGE registry (6) – 6 Middle Eastern Gulf countries 
J-TRACE (7) – Japan Thrombosis Registry for atrial fibrillation, coronary or cerebrovascular events 
  
7 Conclusion 
AF affects millions of people worldwide and, left untreated, increases the risk and severity of stroke and heart 
failure. While guidelines for the screening, diagnosis and management of AF exist, there are gaps in implementation 
of these guidelines globally, and in particular in LMICs. Long distances to health facilities, a shortage of trained 
health professionals and low awareness of and adherence to OAC treatment among health professionals and patients 
may all serve as roadblocks to guideline adherence. This Roadmap identifies some potential solutions, such as 
NPHW-led AF screening programs, the use of novel telemedicine technologies and OAC education interventions, 
all of which may be feasible strategies for improving AF outcomes in low-resource settings. It also highlights areas 
where more research is needed, for example on determinants and primary prevention of AF, the cost-effectiveness 
of novel technologies and telemedicine for screening and diagnosis of AF in LMICs, gaps in management of AF in 
LMICs and the feasibility of NPHW-led interventions to improve AF management in these contexts. While this 
Roadmap can serve as guidance on potential strategies for improved AF screening, diagnosis and management in 
LMICs, the applicability of these strategies to specific LMIC settings must be considered further. 
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